It has been recently demonstrated that EGFR inhibition by erlotinib in non-small cells lung cancer, independent of the EGFR mutation status, induced downregulation of miR-21, which in turn increased TNFα mRNA stability and its protein synthesis. Here, EGFR is linked to non-small cell lung carcinoma.